Stock price when the opinion was issued
NA's leading death-care company. Consolidator in a fragmented industry. 15-16% market share. Size and scale are a meaningful advantage, as is financial strength. Two closest rivals are encountering financial difficulties. 30% ROE and rising.
After a couple of tough Covid years, should return to historic 14% earnings as well as dividend growth. Good combination of value and high-visibility, non-cyclical, non-discretionary growth. Testing all-time highs. Yield is 1.7%.
(A Top Pick Aug 17/16. Up 34.4%.) A very boring, steady business that is probably going to improve over time. A really well run business and he likes management. Felt it became fully priced, and would look for a better entry price.